Amarin corporation plc AMRN.US Overview
AMRN AI Analysis & Strategy
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
AMRN Current Performance
0.48%
Amarin corporation plc
0.98%
Avg of Sector
0.83%
S&P500
AMRN Key Information
AMRN Financial Forecast
Unit : USD
AMRN Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | -0.04 | -300% | -96.4% | 41.04M | -45.6% | -9.3% | -78% |
| 2024Q2 | -0.05 | 0% | 0% | 42.3M | -36% | 33.5% | 2.3% |
| 2024Q1 | 0.01 | -50% | 100% | 67.57M | -15.7% | 66.4% | -17.6% |
| 2023Q4 | -0.01 | -150% | 33.3% | 56.49M | -34.3% | 10.7% | -7.7% |
| 2023Q3 | -0.01 | -150% | 66.7% | 75.36M | -16.5% | 18.1% | -29.2% |
AMRN Profile
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.